We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
RNS Number : 7128V
Clinigen Group plc
07 November 2017
7 November 2017
Grant of Share Options
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 6 November 2017, the following Directors were granted share options over a total of 122,995 ordinary shares of 0.1 pence each ("Ordinary Shares"), granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 16 October 2020 subject to the achievement of certain performance criteria.
The additional share options granted to Shaun Chilton are in relation to the completion of the acquisition of Quantum Pharma plc.
Director/PDMR Number Total number Total number Total number of share of share of ordinary of ordinary options options shares shares granted now held now held (excluding share options) as % issued share capital --------------- ---------- ------------- ------------- ---------------- Shaun Chilton 43,630 318,420 312,943 0.26% --------------- ---------- ------------- ------------- ---------------- Chris Rigg 79,365 79,365 6,563 0.01% --------------- ---------- ------------- ------------- ----------------
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495010 Shaun Chilton, Group Chief Executive Officer Martin Abell, Group Chief Financial Officer Numis Securities Limited Tel: +44 (0) 20 7260 1000 Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) RBC Capital Markets - Joint Tel: +44 (0) 20 Broker 7653 4000 Marcus Jackson / Elliot Thomas / Jack Wood Instinctif Partners Tel: +44 (0) 20 7457 2020 Melanie Toyne-Sewell / Alex Shaw / Deborah Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBFBRTMBBMBIR
(END) Dow Jones Newswires
November 07, 2017 05:00 ET (10:00 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions